Table 5.
Reference | Sweeteners/Doses/Duration | Design | Results/Conclusions Saccharin and Sucralose |
---|---|---|---|
Serrano et al., 2021 [46] | Saccharin 400 mg/d/2 wk |
Randomized, double-blind, placebo-controlled interventional study | ↔gut microbiota |
Ahmad et al., 2020 [59] | Sucralose and aspartame 20% ADI sucralose (~0.136 g sucralose)/14 d |
Randomized, double-blind crossover (12 wk) and controlled clinical trial. | ↔ gut microbiota ↔ SCFAs |
Thomson et al., 2019 [60] | Sucralose 780 mg/d/7 d |
Randomized, double-blind study | ↔ gut microbiota |
Suez et al., 2014 [34] | Saccharin FDA maximal ADI/7 d |
Intervention study | Response according to basal microbiota |
ADI: Acceptable daily intake; SCFA: short-chain fatty acid; d: day; wk: weeks. ↔: unmodified